Mechanism of Action
Mu-Opioid Receptor Activation
BCM-7 is a partial agonist at mu-opioid receptors with Ki ~100 nM, considerably lower potency than morphine (Ki ~1 nM). At physiological GI concentrations reached during casein digestion, BCM-7 can inhibit intestinal motility (via mu-opioid receptors on enteric neurons) and modulate gut secretion. The peptide is normally degraded rapidly by gut peptidases; systemic absorption in healthy adults is negligible.
A1 vs A2 Casein Distinction
A1 beta-casein (common in Holstein cattle, prevalent in European-origin breeds) contains a histidine at position 67, creating a protease-sensitive site that releases BCM-7 during digestion. A2 beta-casein (original cattle variant, present in Guernsey, Jersey breeds, goat/sheep milk) has a proline at position 67, blocking BCM-7 release. This structural difference underlies the A2 milk hypothesis, though the health implications remain debated.
Research Summary
Gut Motility and Digestion
Preclinical/Some ClinicalBCM-7 slows intestinal transit in animal models via mu-opioid receptor activation on enteric neurons. Randomized crossover trials comparing A1 vs A2 milk consumption show that A2 milk causes less bloating, softer stools, and lower BCM-7 urinary excretion in adults with mild lactose intolerance symptoms. These GI effects are the most consistently replicated BCM-7 effects in humans.
Autism Hypothesis
Controversial/UnsupportedThe "opioid excess" theory of autism proposed that BCM-7 (and gluten-derived gliadorphin) crosses a leaky gut BBB in susceptible individuals, causing opioid receptor-mediated behavioral effects. Despite widespread interest, this hypothesis lacks robust clinical validation. Casein-free diets in autism studies show inconsistent results. Major autism research organizations do not recommend casein-free diets based on current evidence.
Cardiovascular Epidemiology
Epidemiological/InconclusiveEarly ecological studies correlated A1 milk consumption with higher cardiovascular disease and type 1 diabetes rates in different countries. These epidemiological associations have not been replicated in controlled studies and likely reflect confounding factors. Current evidence does not support a causal role for BCM-7 in cardiovascular disease.
Calculate your Casomorphin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Gut motility inhibition (rodent) | 1-10 mg/kg IP | Single injection | Intraperitoneal |
| A1 vs A2 milk GI symptoms (human) | Standard serving of A1 or A2 milk | Daily for crossover period | Oral (dietary) |
| BCM-7 urinary excretion quantification | N/A | Post-milk consumption | Urine collection (ELISA/MS) |
Casomorphins are food-derived peptides, not administered as research compounds in typical settings. Their study involves dietary interventions and GI peptidase inhibition models.
Interactions
Safety Profile
BCM-7 from dietary casein is safe for the vast majority of people; it is a normal product of milk digestion and has been consumed by humans for millennia. The opioid activity is very weak and systemic absorption in healthy adults is negligible due to gut peptidase activity and intestinal barrier function. The autism casein-free diet is not harmful but also not evidence-based. A2 milk is a commercially available alternative for those with GI sensitivity to A1 casein digestion.
References
- [1]Teschemacher H, et al. Milk protein-derived opioid receptor ligands. Biopolymers. 1997;43(2):99-117.
- [2]Ho S, et al. Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study. Eur J Clin Nutr. 2014;68(9):994-1000.
- [3]Barnett MP, et al. Dietary A1 beta-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 beta-casein in Wistar rats. Int J Food Sci Nutr. 2014;65(6):720-727.